This module uses fundamental data of Coya Therapeutics, to approximate the value of its Beneish M Score. Coya Therapeutics, M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Coya Therapeutics, Piotroski F Score and Coya Therapeutics, Altman Z Score analysis.
Coya
Beneish M Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Investments
Stock Based Compensation
Begin Period Cash Flow
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Net Working Capital
Non Currrent Assets Other
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Gross Profit
Net Income From Continuing Ops
Probability Of Bankruptcy
At present, Coya Therapeutics,'s Net Debt To EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Interest Debt Per Share is expected to grow to 1.46, whereas Net Debt is projected to grow to (36.4 M). At present, Coya Therapeutics,'s Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Cash Per Share is expected to grow to 2,642, whereas PTB Ratio is forecasted to decline to 0.
At this time, Coya Therapeutics,'s M Score is unavailable. The earnings manipulation may begin if Coya Therapeutics,'s top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Coya Therapeutics, executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Coya Therapeutics,'s earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Coya Therapeutics,'s auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Coya Therapeutics, Common Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Coya Therapeutics,'s different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Coya Therapeutics, in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Coya Therapeutics,'s degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization
23,393.66
At present, Coya Therapeutics,'s Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting.
Coya Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Coya Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Coya Therapeutics,'s managers, analysts, and investors.
Environmental
Governance
Social
About Coya Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coya Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coya Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coya Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.98)
Revenue Per Share
0.687
Return On Assets
(0.29)
Return On Equity
(0.51)
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.